TAK 754
Alternative Names: BAX 888; FVIII gene therapy; SHP-654; TAK-754Latest Information Update: 30 Oct 2021
Price :
$50 *
At a glance
- Originator Baxalta
- Developer Takeda
- Class Gene therapies
- Mechanism of Action Blood coagulation factor replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Haemophilia A